KRAS and neoplasm: As an example, Bolivar et al. reported that 94% of a 48-patient cohort carried at least one EC-associated mutation—commonly in CTNNB1, KRAS, PTEN, or PIK3CA—although only one-third of those cases shared an identical mutation in the tumor itself [28].